Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Drug screening for genetic disorders (Yissum)


總結

Human pluripotent stem cells (hPSC) genetic manipulation had been developed to establish models for human genetic disorders such as fragile X syndrome, Down syndrome, and Prader-Willi syndrome (and others) as well as some genetic cancers (such as retinoblastoma) and genetic diabetes (Mody1, Mody4)
Overall, the group has developed 15 disease models for 13 genetic disorders (complex disorders).
Numerous developmental diseases cannot be studied through animal models, nor by isolating cells from patients. In such cases, hPSC can be used as a complementary model system that overcomes these impediments.
We propose using these models as platforms for screening small molecules to treat these genetic disorders, as well as validating their potential therapy for human developmental genetic disorders.Human pluripotent stem cells (hPSC) may give rise to most human body cell types, and as such they hold the promise to change the face of biomedical research and therapy
We demonstrated genetic manipulation of hPSC to establish models for human genetic disorders.
Using these models, we have unravelled the molecular basis of genetic disorders, and identified a paradigm treatment for disorders such fragile X syndrome and Lesch-Nyhan disease.


技術優勢

Novel models for human developmental genetic disorders are used to unravel the molecular basis of the disorders and identified a paradigm treatment thereof.
A powerful high screening tool for small molecules to treat rare and genetic disorders.
We are currently gathering novel information on the basis of 13 genetic diseases, as well as developing new therapies to treat them.


技術應用

High throughput screening of small molecules for those indications
Rational selection of a drug based on the pathological mechanism of the disease in question.


ID號碼

7-2015-3118


國家/地區

以色列

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版